Evaluation of the circulating CD34 + , CD309 + , and endothelial progenitor cells in patients with first attack of optic neuritis

Etemadifar, Masoud; Dehghani, Leila; Ganji, Hamid; Soleimani, Reza; Talebi, Maedeh; Eskandari, Nahid; Samani, Fazel Sahraneshin; Meamar, Rokhsareh

Evaluation of the circulating CD34 + , CD309 + , and endothelial progenitor cells in patients with first attack of optic neuritis

Authors

¹ Isfahan Multiple Sclerosis and Neuroimmunology Research Center, Isfahan Eye Research Center, Ophthalmology Ward, Feiz Hospital, Isfahan, Iran

² Isfahan Neurosciences Research Center, AlZahra Hospital, Isfahan, Iran

³ Alzahra University Hospital Manager, Isfahan University of Medical Sciences, Isfahan, Iran

⁴ Department of Biology, Payam Noor University, Isfahan, Iran

⁵ Biochemistry Labratory, Isfahan Al-Zahra Hospital, Isfahan, Iran

⁶ Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

⁷ Department of Stem Cells, Royan Institute, Tehran, Iran

⁸ Isfahan Neurosciences Research Center, AlZahra Hospital; Alzahra University Hospital Manager, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Endothelial progenitor cells (EPCs) are present in circulation and contribute to vasculogenesis in adults. The aim of the present study was to determine the number of circulating EPCs in patients with optic neuritis (ON).
Materials and Methods : Fifty patients with ON were diagnosed by expert neurologist and optometrist at the Feiz Hospital, Isfahan, Iran (2012-2013). Blood samples were collected from ON patients in the first attack. The number of EPCs was measured by flow cytometry through the assessment of CD34 ⁺ and CD309 ⁺ in patients and healthy individuals.
Results : With using flow cytometry, CD34 ⁺ and CD309 ⁺ cells detected in peripheral blood cells of patients (n = 50) with ON, and healthy individuals (n = 30). Patients with ON had (mean = 66.71 ± 17.82) CD34 ⁺ and CD309 ⁺ cells compared with healthy controls (mean = 28.72 ± 22.46). In addition, there was no significant difference in CD309 ⁺ cells in both groups.
Conclusion: This study showed elevated CD34 ⁺ and CD309 ⁺ cells in the early stage of the disease. Regarded to EPC increment in neural repair, it expected the EPC level be increased in these patients, but no detectable differences were observed among both markers in healthy and patient with first attack.

Keywords

References

1.	Morrow MJ, Wingerchuk D. Neuromyelitis optica. J Neuroophthalmol 2012;32:154-66.
2.	Lidster K, Baker D. Optical coherence tomography detection of neurodegeneration in multiple sclerosis. CNS Neurol Disord Drug Targets 2012;11:518-27.
3.	Etemadifar M, Abtahi SH, Razmjoo H, Abtahi MA, Dehghani A, Salari M, et al. 25-hydroxyvitamin D concentrations in patients with optic neuritis as a clinically isolated syndrome and healthy controls. Int J Prev Med 2012;3:313-7. [PUBMED]
4.	Dehghani L, Meamar R, Etemadifar M, Sheshde ZD, Shaygannejad V, Sharifkhah M, et al. Can vitamin d suppress endothelial cells apoptosis in multiple sclerosis patients? Int J Prev Med 2013;4:S211-5.
5.	Ghani U, Shuaib A, Salam A, Nasir A, Shuaib U, Jeerakathil T, et al. Endothelial progenitor cells during cerebrovascular disease. Stroke 2005;36:151-3.
6.	Lund H, Krakauer M, Skimminge A, Sellebjerg F, Garde E, Siebner HR, et al. Blood-brain barrier permeability of normal appearing white matter in relapsing-remitting multiple sclerosis. PLoS One 2013;8:e56375.
7.	Minagar A, Maghzi AH, McGee JC, Alexander JS. Emerging roles of endothelial cells in multiple sclerosis pathophysiology and therapy. Neurol Res 2012;34:738-45.
8.	Minagar A, Jy W, Jimenez JJ, Alexander JS. Multiple sclerosis as a vascular disease. Neurol Res 2006;28:230-5.
9.	Friese MA, Fugger L. Pathogenic CD8(+) T cells in multiple sclerosis. Ann Neurol 2009;66:132-41.
10.	Alexander JS, Zivadinov R, Maghzi AH, Ganta VC, Harris MK, Minagar A. Multiple sclerosis and cerebral endothelial dysfunction: Mechanisms. Pathophysiology 2011;18:3-12.
11.	Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005;353:999-1007.
12.	Dong C, Goldschmidt-Clermont PJ. Endothelial progenitor cells: A promising therapeutic alternative for cardiovascular disease. J Interv Cardiol 2007;20:93-9.
13.	Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, Murayama T, et al. Statin therapy accelerates reendothelialization: A novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002;105:3017-24.
14.	Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation: Part I. Circulation 2003;108:1917-23.
15.	Schmidt-Lucke C, Rössig L, Fichtlscherer S, Vasa M, Britten M, Kämper U, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: Proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005;111:2981-7.
16.	Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002;106:653-8.
17.	Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999;18:3964-72.
18.	Targonski PV, Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Lerman A. Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation 2003;107:2805-9.
19.	Sobrino T, Hurtado O, Moro MA, Rodríguez-Yáñez M, Castellanos M, Brea D, et al. The increase of circulating endothelial progenitor cells after acute ischemic stroke is associated with good outcome. Stroke 2007;38:2759-64.
20.	Kong D, Melo LG, Gnecchi M, Zhang L, Mostoslavsky G, Liew CC, et al. Cytokine-induced mobilization of circulating endothelial progenitor cells enhances repair of injured arteries. Circulation 2004;110:2039-46.
21.	Griese DP, Ehsan A, Melo LG, Kong D, Zhang L, Mann MJ, et al. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: Implications for cell-based vascular therapy. Circulation 2003;108:2710-5.
22.	Fujiyama S, Amano K, Uehira K, Yoshida M, Nishiwaki Y, Nozawa Y, et al. Bone marrow monocyte lineage cells adhere on injured endothelium in a monocyte chemoattractant protein-1-dependent manner and accelerate reendothelialization as endothelial progenitor cells. Circ Res 2003;93:980-9.
23.	Navarro-Sobrino M, Rosell A, Hernandez-Guillamon M, Penalba A, Ribó M, Alvarez-Sabín J, et al. Mobilization, endothelial differentiation and functional capacity of endothelial progenitor cells after ischemic stroke. Microvasc Res 2010;80:317-23.
24.	Assmus B, Iwasaki M, Schächinger V, Roexe T, Koyanagi M, Iekushi K, et al. Acute myocardial infarction activates progenitor cells and increases Wnt signalling in the bone marrow. Eur Heart J 2012;33:1911-9.
25.	Yip HK, Chang LT, Chang WN, Lu CH, Liou CW, Lan MY, et al. Level and value of circulating endothelial progenitor cells in patients after acute ischemic stroke. Stroke 2008;39:69-74.
26.	Ghani U, Shuaib A, Salam A, Nasir A, Shuaib U, Jeerakathil T, et al. Endothelial progenitor cells during cerebrovascular disease. Stroke 2005;36:151-3.
27.	Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000;95:952-8.
28.	26. Urbich C, Dimmeler S. Endothelial progenitor cells: Characterization and role in vascular biology. Circ Res 2004;95:343-53.
29.	Hristov M, Erl W, Weber PC. Endothelial progenitor cells: Mobilization, differentiation, and homing. Arterioscler Thromb Vasc Biol 2003;23:1185-9.
30.	Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003;348:593-600.
31.	28. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-60.
32.	Urbich C, Heeschen C, Aicher A, Dernbach E, Zeiher AM, Dimmeler S. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 2003;108:2511-6.
33.	Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999;85:221-8.
34.	Tao J, Wang Y, Yang Z, Tu C, Xu MG, Wang JM. Circulating endothelial progenitor cell deficiency contributes to impaired arterial elasticity in persons of advancing age. J Hum Hypertens 2006;20:490-5.
35.	Yip HK, Chang LT, Chang WN, Lu CH, Liou CW, Lan MY, et al. Level and value of circulating endothelial progenitor cells in patients after acute ischemic stroke. Stroke 2008;39:69-74.
36.	Bogoslovsky T, Chaudhry A, Latour L, Maric D, Luby M, Spatz M, et al. Endothelial progenitor cells correlate with lesion volume and growth in acute stroke. Neurology 2010;75:2059-62.
37.	Sobrino T, Hurtado O, Moro MA, Rodríguez-Yáñez M, Castellanos M, Brea D, et al. The increase of circulating endothelial progenitor cells after acute ischemic stroke is associated with good outcome. Stroke 2007;38:2759-64.

Advanced Biomedical Research